Press Releases

Date Title  
Toggle Summary Collegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from
Toggle Summary Collegium Reports Third Quarter Financial Results
Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017 Thirteen exclusive ER oxycodone formulary wins announced for Xtampza ER effective January 1, 2019 Cash increased by $6.0 million , to $139.8 million as of September 30, 2018 ; raising
Toggle Summary Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
STOUGHTON, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone DETERx ® formulation (Xtampza ® ER),” in the peer-reviewed medical journal, Journal of Opioid Management .
Toggle Summary Collegium to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update
STOUGHTON, Mass. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 8, 2018 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and
Toggle Summary Collegium to Present at Upcoming Investor Conference
STOUGHTON, Mass. , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will present at the following investor conference in October: The Cantor Global Healthcare Conference on Tuesday, October 2 nd at 2:50 p.m.
Toggle Summary Collegium Announces Scientific Presentations at PAINWeek 2018 Meeting
STOUGHTON, Mass. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in Las Vegas .
Toggle Summary Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Net revenue $73.1 million for the second quarter of 2018, 1,952% increase vs second quarter 2017, 15% vs first quarter 2018 Xtampza ER prescriptions grew by 23% in the second quarter of 2018 Cash balance at end of 2018 anticipated to be at least $135.0 million Conference call scheduled for today at
Toggle Summary Collegium to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass. , July 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Announces Promotion of Scott Dreyer to CCO
CANTON, Mass. , July 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective July 10, 2018 . Mr. Dreyer brings over 25 years of commercial leadership
Toggle Summary Collegium Announces CEO Succession
Joseph Ciaffoni Promoted to CEO and Appointed to Board Michael Heffernan Continues to serve as Chairman of the Board CANTON, Mass. , June 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that Joseph Ciaffoni , Executive Vice President and Chief Operating
Toggle Summary Collegium to Present at Upcoming Investor Conferences
CANTON, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: The Jefferies Global Healthcare Conference on Thursday, June 7 th at 9:30 a.m.
Toggle Summary Collegium Reports First Quarter Financial Results and Provides Corporate Update
Net revenue of $63.7 million , compared to $10.8 million in Q4 2017  Xtampza ER prescriptions grew by 72% in the first quarter Integration of the Nucynta franchise into the commercial organization Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass.
Toggle Summary Collegium to Present at the Deutsche Bank Health Care Conference
CANTON, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43 rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston .
Toggle Summary Collegium to Host Conference Call to Discuss First Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass. , April 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium to Present at the H.C. Wainwright Global Life Sciences Conference
CANTON, Mass. , April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco .
Toggle Summary Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel
CANTON, Mass. , March 19, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, effective March 16, 2018 . Ms.
Toggle Summary Collegium to Present at Upcoming Investor Conferences
CANTON, Mass. , March 16, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in March: The Oppenheimer & Company 28 th Annual Healthcare Conference on Wednesday, March 21 st at 9:10 a.m.
Toggle Summary Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
Xtampza ER prescriptions grew by 37% in the fourth quarter FDA Approval of sNDA, including Comparative OxyContin Data in label Expanded product portfolio by licensing rights to commercialize Nucynta franchise Revenue growth and strong balance sheet provide cash runway into 2020 Conference call
Toggle Summary Collegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise
Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium’s existing commercial infrastructure CANTON, Mass. , Jan.